ACRS Aclaris Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1557746 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-59.3%
TTM net income YoY43.8%
TTM EPS YoY62.7%
Revenue 3-yr CAGR-33.2%
Net income 3-yr CAGR—
Margins
Gross margin79.2%
Operating margin-1,414.0%
Net margin-1,244.1%
FCF margin-1,176.6%
EBITDA margin-1,407.5%
Returns
ROE-55.5%
ROA-40.7%
ROIC (approx.)-59.3%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets22.8%
Debt / equity0.00x
Current ratio5.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.83M | $18.72M |
| Cost of revenue | $2.09M | $2.79M |
| Gross profit | $5.74M | $15.93M |
| R&D expense | $52.65M | $33.59M |
| SG&A expense | $21.97M | $22.20M |
| Operating income | -$76.38M | -$141.93M |
| Pretax income | -$64.92M | -$132.06M |
| Net income | -$64.92M | -$132.06M |
| EBITDA | -$75.92M | -$141.12M |
| EPS (basic) | -0.53 | -1.71 |
| EPS (diluted) | -0.53 | -1.71 |
| Weighted avg. shares (diluted) | 122.56M | 77.30M |
| Balance sheet | ||
| Cash & equivalents | $19.96M | $24.57M |
| Short-term investments | $70.79M | $89.02M |
| Receivables | — | $318,000 |
| Current assets | $96.32M | $125.95M |
| PP&E, net | $761,000 | $1.01M |
| Total assets | $160.46M | $220.33M |
| Current liabilities | $28.64M | $31.60M |
| Total liabilities | $57.38M | $64.77M |
| Shareholders' equity | $103.08M | $155.55M |
| Shares outstanding | 120.50M | 107.85M |
| Cash flow statement | ||
| Operating cash flow | -$47.11M | -$20.07M |
| Capital expenditure | $111,000 | $121,000 |
| Free cash flow | -$47.22M | -$20.20M |
| Investing cash flow | $48.37M | -$69.77M |
| Financing cash flow | -$5.86M | $74.54M |
| Depreciation & amortization | $454,000 | $807,000 |
| Stock-based compensation | $12.38M | $10.86M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.